Angiogenesis-related molecular targets in esophageal cancer

Bibliography

• Shimada Y, Sato F. Molecular factors related to metastasis of esophageal squamous cell carcinoma. Esophagus 2007;4:7-18
   Google Scholar
• Chung CS, Lee YC, Wang CP, Secondary prevention of esophageal squamous cell carcinoma in areas where smoking, alcohol, and betel quid chewing are prevalent. J Formos Med Assoc 2010;109:408-21
   PubMed Web of Science ®Google Scholar
• Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett 2009;275:170-7
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Toi M, Kawada K, Kawano T. Angiogenesis in superficial esophageal squamous cell carcinoma: magnifying endoscopic observation and molecular analysis. Dig Endosc 2010;22:259-67
   PubMed Web of Science ®Google Scholar
• Lo PH, Lung HL, Cheung AK, Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res 2010;70:5567-76
   PubMed Web of Science ®Google Scholar
• Chen L, Di D, Luo G, Immunochemical staining of MT2-MMP correlates positively to angiogenesis of human esophageal cancer. Anticancer Res 2010;30:4363-8
   PubMed Web of Science ®Google Scholar
• Takeuchi K. Prostaglandin EP receptors and their roles in mucosal protection and ulcer healing in the gastrointestinal tract. Adv Clin Chem 2010;51:121-44
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD. Clinical application of therapies targeting VEGF. Cell 2010;143:13-16
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Li S, The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010;10:1693-701
   PubMed Web of Science ®Google Scholar
• Lee W, Patel JH, Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs 2009;18:1351-64
   PubMed Web of Science ®Google Scholar
• Mitchell DC, Bryan BA. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors. J Cell Biochem 2010;111:543-53
   PubMed Web of Science ®Google Scholar
• Tysome JR, Lemoine NR, Wang Y. Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes. Curr Opin Mol Ther 2009;11:664-9
   PubMed Web of Science ®Google Scholar
• Evensen L, Link W, Lorens JB. Imaged-based high-throughput screening for anti-angiogenic drug discovery. Curr Pharm Des 2010;16:3958-63
   PubMed Web of Science ®Google Scholar
• Hong L, Fan D. Cancer mucosa antigens: novel immunotherapeutic targets. Expert Opin Ther Targets 2008;12:749-56
   PubMed Web of Science ®Google Scholar
• Bradbury PA, Zhai R, Ma C, Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009;15(14):4680-5
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ishiguro H, Kuwabara Y, Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010;29:83
   PubMed Web of Science ®Google Scholar
• Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 2010;21:112-17
   PubMed Web of Science ®Google Scholar
• Frentzen A, Yu YA, Chen N, Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA. 2009;106:12915-20
   PubMed Web of Science ®Google Scholar
• Ewan S. Black sheep of the VEGF family gives hope for cancer therapy. Drug Discov Today 2005;10:6
   PubMed Web of Science ®Google Scholar
• Cho DC, Puzanov I, Regan MM, Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009;32:181-5
   PubMed Web of Science ®Google Scholar
• Modarai B, Humphries J, Burnand KG, Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution. Arterioscler Thromb Vasc Biol 2008;28:1753-9
   PubMed Web of Science ®Google Scholar
• Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13:223-30
   PubMed Web of Science ®Google Scholar
• Black JM, Hodari KT, Rogers N, Exudative, nonhealing scalp: a complication of systemic chemotherapy with capecitabine and bevacizumab. Arch Dermatol 2011;147(1):134-5
   PubMed Web of Science ®Google Scholar
• Meza-Junco J, Wong C, Fields A, Sawyer MB. Esophageal ulcer in a patient who received bevacizumab. Invest New Drugs 2010;28(1):98-101
   PubMed Web of Science ®Google Scholar
• Beaumont I. The use of bevacizumab for the treatment of colorectal cancer. Int J Palliat Nurs 2010;16(12):576-78
   PubMedGoogle Scholar
• Burns TF, Juergens RA. Bevacizumab in advanced lung cancer: in search of the right drug for the right patient. Oncology (Williston Park) 2010;24(13):1223-4
   PubMed Web of Science ®Google Scholar
• Li J, Merl MY, Chabot J, Saif MW. Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4-8, 2010. JOP 2010;11:310-2
   Google Scholar
• Provencio M, Sánchez A, Garrido P, Valcárcel F. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 2010;11:91-7
   PubMed Web of Science ®Google Scholar
• Blanke CD, Huse DM. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. J Med Econ 2010;13:681-90
   PubMedGoogle Scholar
• Pal SK, Figlin RA, Yu H. Deciphering the anticancer mechanisms of sunitinib. Cancer Biol Ther 2010;10:712-14
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Schutz FA, Je Y, Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280-5
   PubMed Web of Science ®Google Scholar
• Hou MM, Hsieh JJ, Chang NJ, Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clin Drug Investig 2010;30:799-804
   PubMed Web of Science ®Google Scholar
• Sun W, Powell M, O'Dwyer PJ, Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947-51
   PubMed Web of Science ®Google Scholar
• Suda K, Murakami I, Katayama T, Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16:5489-98
   PubMed Web of Science ®Google Scholar
• Kaneko K, Kumekawa Y, Makino R, EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 2010;15:65-72
   Web of Science ®Google Scholar
• Pesek M, Benesova L, Belsanova B, Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res 2009;29:2767-73
   PubMed Web of Science ®Google Scholar
• Kanashiro CA, Schally AV, Zarandi M, Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncol 2007;30:1019-28
   PubMed Web of Science ®Google Scholar
• Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007;254:165-77
   PubMed Web of Science ®Google Scholar
• Beydoun SR, Shatzmiller RA. Chronic immune-mediated demyelinating polyneuropathy in the setting of cetuximab treatment. Clin Neurol Neurosurg 2010;112:900-2
   PubMed Web of Science ®Google Scholar
• Nestor M, Sundstrom M, Anniko M, Tolmachev V. Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas. Nucl Med Biol 2011;38(1):103-12
   PubMed Web of Science ®Google Scholar
• Kuhnt T, Sandner A, Wendt T, Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2010;21:2284-9
   PubMed Web of Science ®Google Scholar
• Schmiedel J, Blaukat A, Li S, Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 2008;13:365-73
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T, A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80
   PubMed Web of Science ®Google Scholar
• Reck M, van Zandwijk N, Gridelli C, Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010;5:1616-22
   PubMed Web of Science ®Google Scholar
• Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2010;11(8):1343-57
   PubMed Web of Science ®Google Scholar
• Merlo V, Longo M, Novello S, Scagliotti GV. EGFR pathway in advanced non-small cell lung cancer. Front Biosci 2011;3:501-17
   Google Scholar
• Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-19
   PubMed Web of Science ®Google Scholar
• Li G, Hu W, Wang J, Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 2010;78:1407-12
   PubMed Web of Science ®Google Scholar
• Bizari L, Borim AA, Leite KR, Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet 2006;165:41-50
   PubMed Web of Science ®Google Scholar
• Milano F, Guarriera M, Rygiel AM, Krishnadath KK. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS One 2010;5:12424
   Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
   PubMed Web of Science ®Google Scholar
• Lin CC, Yang JC. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. Drugs 2011: published online 1 Jan 2011, doi:10.2165/11587560-000000000-00000
   Google Scholar
• Looby E, Abdel-Latif MM, Athié-Morales V, Deoxycholate induces COX-2 expression via Erk1/2-, p38-MAPK and AP-1-dependent mechanisms in esophageal cancer cells. BMC Cancer 2009;9:190
   PubMed Web of Science ®Google Scholar
• Hu HM, Kuo CH, Lee CH, Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterol 2009;9:37
   PubMed Web of Science ®Google Scholar
• Moons LM, Kuipers EJ, Rygiel AM, COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol 2007;102:2373-9
   Google Scholar
• Lu G, Liu Y, Ji B, Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. Cancer Invest 2010;2:629-34
   Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251:1056-63
   PubMed Web of Science ®Google Scholar
• Rabasseda X, Gomez-Zaera M. A report from the 46th Annual Meeting of the American Society of Clinical Oncology (June 4-8, 1020 - Chicago, Illinois, USA). Drugs Today (Barc) 2010;46:699-731
   PubMedGoogle Scholar